

**BELLATRIX**

ASSET MANAGEMENT

HARVEST INVESTMENT FUND Global Convertible**JANUARY 2021****SUBFUND OVERVIEW**

The fund's objective is to generate long-term capital appreciation by investing in a global portfolio composed principally of convertible bonds without any geographical or currency limitation. Convertible bonds are sensitive to movements in equities, credit, interest rates and volatility. Thus, according to the manager's macroeconomic assumptions, the portfolio parameters are set, with a bond or an equity bias. Thereafter, a selection process picks and weights around 50 to 60 investments to structure the portfolio. The fund is not benchmarked.

INVESTMENT MANAGER'S COMMENTS

January 2021 has been of the very same vintage as the millesime 2020: excellent.

Convertible bonds continued to do well, not only in terms of performance but above all in terms of performance compared to the risk (because of asymmetric behaviour, cheap valuation to model, bond floor...). This is the beauty of the asset class, especially with buoyant markets, compared to equity. Convertibles have a bond floor on the downside and ratchet clauses to increase M&A premium return. Thus, the primary market continued to do well in terms of volume, with record new issues, illustrating investor interest. Nevertheless, global convertible bonds are now expensive compared to their mathematical valuation, which means that selection will be key, but Asia remains at discount level.

To focus on our investment portfolio, the main positive contributors were **Zur Rose 2.75% 2025** and **Teladoc 1.375% 2025**. Both are leaders: Teladoc in telemedicine and virtual healthcare, Zur Rose as Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. CEO Jason Gorevic, has been rolling out Teladoc's business vision for over a decade. The company has grown through acquisitions (including Livongo Health) and organic growth as it aims to penetrate a high-growth, disruptive field that has been accelerated

by the COVID-19 pandemic. Teladoc is projecting full-year 2020 revenue over \$1 billion due to surging demand for virtual care services during the coronavirus pandemic. As for Zur Rose, it may be in Amazon's viewfinder as its purchase would enable Amazon to get into e-pharmacy directly, acquiring a sector leader and its logistics.

On the other side, **Endeavour Mining 3% 2023**, despite just turning net cash positive and now being one of the top 15 global gold producers, was down for the month. Average analysts' target price is more than 50% over the actual spot price, the convertible offers a nice bond floor and a very nice upside potential. The strategy is well defined and focused on increasing the quality of the mine portfolio to create a leading African gold producer with low All-In Sustaining Cost (AISC) and long-life mines. Also, after the investment phase of 2017/19, the debt reduction phase of 2019/21, the company is now into the cash-in phase since 2021: harvest time.

Finally, let's mention **Safran 0.875% 2027** which has suffered from delayed estimates post-covid for a catalogued post-covid recovery company. Once again, the global position of the company and its strong shareholder base gives us confidence on the credit side while retaining interest for the long term.

NAV PER SHARE SINCE INCEPTION (CLASS A)**PERFORMANCE**

	HARD CLOSED			
	A	B	C	H
HEDGED	NO	NO	CURRENCIES	CURRENCIES & DELTA
DELTA	56%	56%	56%	0%
VOLATILITY	10,32%	10,32%	11,74%	7,00%
NAV/SHARE	180,52	170,96	142,99	112,49
MONTH	2,10%	2,15%	1,80%	2,57%
2021	2,10%	2,15%	1,80%	2,57%
2020	10,33%	10,99%	13,94%	6,56%
2019	12,13%	12,72%	10,73%	-0,59%
2018	-1,27%	-0,65%	-5,32%	-0,66%
2017	4,90%	5,33%	10,40%	-0,19%
2016	0,50%	1,20%	-2,11%	-5,97%
2015	4,69%	5,37%	-1,58%	0,95%
2014	14,17%	14,85%	5,59%	9,85%





MAIN HOLDINGS

TOP 10	CCY	MATURITY / DURATION	PUT	%	DELTA	CURRENT YIELD
TELADOC HEALTH 1.375% 2025	USD	15/05/2025		3,75%	100%	0,28%
ZUR ROSE 2.75% 2025	CHF	31/03/2025		3,10%	99%	0,90%
SERVICE NOW 0% 2022	USD	01/06/2022		3,07%	100%	0,00%
MITHRA PHARMACEUTICALS 4.25% 2025	EUR	17/12/2025		2,78%	48%	4,19%
SONY CORPORATION 0% 2022	JPY	30/09/2022		2,76%	100%	0,00%
ENDEAVOUR MINING 3% 2023	USD	15/02/2023		2,61%	48%	2,63%
JP MORGAN CHASE/TENCENT 0% 2022	USD	07/08/2022		2,48%	91%	0,00%
ANLLIAN CAPITAL/ANTA SPORTS 0% 2025	EUR	05/02/2025	05/02/2023	2,43%	79%	0,00%
FORTIS CASHES Float 2049	EUR			2,36%	7%	2,44%
BANK OF AMERICA 7.25% PERP	USD			2,23%	0%	6,59%
NAV		4,02		100%	56%	1,33%

TOP 5 / BOTTOM 5 (ATTRIBUTION)	
ZUR ROSE 2.75% 2025	1,35%
TELADOC HEALTH 1.375% 2025	1,19%
JP MORGAN CHASE/TENCENT 0% 2022	0,57%
HARVEST/HAIER SMART HOME 0% 2022	0,31%
POSEIDON/POSTAL SAVINGS 0% 2025	0,19%
ENDEAVOUR MINING 3% 2023	-0,15%
SAFRAN 0.875% 2027	-0,13%
ARTEMIS/KERING 0% 2023	-0,10%
BANK OF AMERICA 7.25% PERP	-0,08%
LIVE NATION 2.25% 2023	-0,07%

**BELLATRIX**

ASSET MANAGEMENT

HARVEST INVESTMENT FUND Global Convertible**JANUARY 2021****GEOGRAPHIC ALLOCATION****CURRENCY ALLOCATION****SECTOR ALLOCATION****MATURITY ALLOCATION****GENERAL INFORMATION**

SHARE CLASS	ISIN	LAUNCH DATE	MAN. FEE	PERF. FEE	MIN. INVEST.	CLASS SHARES	SUBFUND ASSETS	CUT-OFF
A	LU0442197868	03/08/2009	1,85%	15% ABOVE 3-MONTHS LIBOR EUR (HIGH WATER MARK)	€ 1.000	CAPITALISATION	EUR 53 MILLIONS	DAILY 12:00 AM
B (INSTITUTIONAL)	LU0518233621	12/07/2010	1,20%		€ 1.000.000			
C (CURRENCY HEDGE)	LU0662027985	16/08/2011	1,85%		€ 1.000			
H (DELTA & CCY HEDGE)	LU0944844058	01/07/2013	1,85%		€ 1.000			

DEPOSITARY BANK	VP Bank (Luxembourg) SA	MANAGEMENT COMPANY	Bellatrix Asset Management S.A.
SUBSCRIPTIONS / REDEMPTIONS	VP Fund Solutions (Luxembourg) SA	ADVISOR	Harvest Advisory S.A.
CENTRAL ADMIN / TRANSFER AGENT	FAX +352 404 770 283 TEL +352 404 770 260 FundClients-LUX@vpbank.com		
FUND	HARVEST INVESTMENT FUND 2 Rue Edward Steichen L-2540 Luxembourg	AUDITOR	KPMG Luxembourg Société Coopérative
		LEGAL ADVISOR	Elvinger Hoss Prussen

Investment Manager's comments are expressed by Bellatrix Asset Management S.A.. Periodic reports, the prospectus of the Fund, and the simplified prospectus of the subfund are available on request from Bellatrix Asset Management S.A. or at the registered office of the Fund. The present information note should not be considered as an offer to buy or sell shares. In order to constitute an offer, this document should be accompanied by the prospectus of the Fund, the simplified prospectus of the sub-fund and the latest periodic report. Although they are based on the best possible sources, the figures in this document have not been audited. Past performance is no guarantee of future performance as the net asset value of the portfolio of the sub-fund depends on market developments. Returns are net of management and performance fees.